AbCellera (ABCL) CFO adds 42,600 shares in open-market stock purchase

Rhea-AI Filing Summary

AbCellera Biologics Inc. Chief Financial Officer Andrew Booth reported an open-market purchase of common shares. He bought 42,600 common shares at a price of $3.42 per share, increasing his direct holdings to 195,600 common shares following the transaction. The filing also reports 130,959 common shares held indirectly through his spouse.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Booth Andrew

(Last) (First) (Middle)

C/O ABCELLERA BIOLOGICS INC

150 W 4TH AVENUE

(Street)

VANCOUVER A1

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/27/2026		P	V	42,600	A	$3.42	195,600	D
Common Shares								130,959	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	Tryn Stimart, attorney-in-fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AbCellera (ABCL) CFO Andrew Booth report in this Form 4 filing?

Andrew Booth reported an open-market purchase of AbCellera common shares. The filing shows he acquired 42,600 common shares, which increased his direct ownership and updates both his direct and indirect holdings in the company’s stock.

How many AbCellera (ABCL) shares did CFO Andrew Booth buy and at what price?

Andrew Booth purchased 42,600 AbCellera common shares in an open-market transaction. The reported purchase price was $3.42 per share, as disclosed in the Form 4, reflecting a single non-derivative transaction dated February 27, 2026.

What is Andrew Booth’s direct AbCellera (ABCL) share ownership after this transaction?

After the reported open-market purchase, Andrew Booth directly owns 195,600 AbCellera common shares. This figure represents his direct, non-derivative holdings following the 42,600-share acquisition disclosed in the Form 4 filed for the transaction dated February 27, 2026.

What indirect AbCellera (ABCL) holdings by Andrew Booth’s spouse are disclosed?

The Form 4 discloses 130,959 AbCellera common shares held indirectly by Andrew Booth through his spouse. These shares are classified as indirect ownership, with the nature of ownership specifically noted as “By spouse” in the filing’s ownership details.

Does this AbCellera (ABCL) Form 4 show insider buying or selling activity?

The Form 4 shows insider buying activity by CFO Andrew Booth. He completed an open-market purchase of 42,600 common shares, and no share sales are reported. The filing also notes indirect holdings by his spouse but without a specified buy or sell transaction.